Navigation Links
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Date:12/8/2008

mburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2008, and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

    (1)  Brodsky RA, Young, NS, Antonioli E, et al. Multicenter phase 3 study
         of the complement inhibitor eculizumab for the treatment of patients
         with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840-1847.
    (2)  Hillmen P, Young NS, Schubert J, et al. The complement inhibitor
         eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med.
         2006;355:1233-1243.
    (3)  Levey AS, Coresh J, Balk E, et al. National Kidney Foundation
         Practice Guidelines for Chronic Kidney Disease: evaluation,
         classification, and stratification. Ann Intern Med. 2003;139:137
         147.
    (4)  Hill A, Platts PJ, Smith A et al. The incidence and prevalence of
         paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients
         in Yorkshire [abstract]. Blood. 2006;108(11):985.
    (5)  Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal nocturnal
         haemoglobinuria: long-term follow-up and prognostic factors. Lancet.
         1996: 348:573-577.
    (6)  Parker C, Omine M, Richards S, et al. Diagnosis and management of
         paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709.
    (7)  Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural
         his
'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
2. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
6. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
7. GEN Reports on the Trend Toward Predictive Toxicogenomics
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Mar. 06, 2015 Research and Markets ... "European Patient Handling Equipment Market by Product, by ... Forecast to 2019" report to their offering. ... expected to grow at a double-digit CAGR of 11.4% ... Factors such as rising geriatric population, increasing incidences of ...
(Date:3/6/2015)... , March 6, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... earned a $9 million milestone payment from Biogen Idec ... evaluating ISIS-SMN Rx in infants with spinal muscular ... study of ISIS-SMN Rx, is a randomized, double-blind, ... diagnosed with SMA.  The study will evaluate the efficacy ...
(Date:3/5/2015)...   MeridianRx earned highest possible score ... leading indicators during its recent URAC accreditation review ... very proud of earning this level of accreditation ... Operating Officer of MeridianRx. "It is a testament ... flexibility and innovation." URAC,s leading indicators ...
Breaking Medicine Technology:European Patient Handling Equipment (Wheelchair, Scooters, Bathroom Safety Supply, Mechanical, Ambulatory) Market 2015-2019 2European Patient Handling Equipment (Wheelchair, Scooters, Bathroom Safety Supply, Mechanical, Ambulatory) Market 2015-2019 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5MeridianRx Earns Highest URAC Accreditation Status 2
... the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: ... a Supplemental Biologics License Application (sBLA) with the U.S. Food ... Virus Vaccine).  The file has been accepted by the FDA ... of 2011. "Upon FDA licensure, this new ...
... Agreement With Enter Holdings -- TEL-AVIV, Israel, September 13, 2010 ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Medicine Technology:FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection 2FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection 3FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection 4Elbit Imaging Announces Share Purchase Agreement With Enter Holdings 2Elbit Imaging Announces Share Purchase Agreement With Enter Holdings 3Elbit Imaging Announces Share Purchase Agreement With Enter Holdings 4Elbit Imaging Announces Share Purchase Agreement With Enter Holdings 5Elbit Imaging Announces Share Purchase Agreement With Enter Holdings 6Elbit Imaging Announces Share Purchase Agreement With Enter Holdings 7Elbit Imaging Announces Share Purchase Agreement With Enter Holdings 8Elbit Imaging Announces Share Purchase Agreement With Enter Holdings 9
(Date:3/6/2015)... Santa Clara, CA (PRWEB) March 06, 2015 ... Bryan tickets at Levi's® Stadium in Santa Clara, California. ... it has already hosted a plethora of exciting events. , ... Bryan will bring his popular summer tour to the west ... of the art facility will take place on August 29 ...
(Date:3/6/2015)... Jose, California (PRWEB) March 06, 2015 ... also known as the pharmacokinetics of a drug refers ... a pharmaceutical compound inside an organism. When toxicity studies ... ADME-Tox or ADMET or ADME/Tox. Increasing focus on lowering ... adoption of ADME-toxicology testing worldwide. The traditional drug development ...
(Date:3/6/2015)... 06, 2015 Parents need to start ... of substance use disorders. School programs like DARE, or ... successful. NOPE, or Narcotics Overdose Prevention and Education has ... Healthline News on Feb. 27th. As teens ... opiate drugs, drug prevention proponents are lobbying Florida to ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
(Date:3/6/2015)... DC (PRWEB) March 06, 2015 Magellan ... nation’s only comprehensive source for key trends and statistics ... spend, medical injectables. Executives from Magellan Rx Management will ... Trend Report: Discover Your Hidden Specialty Drug Spend,” a ... Information Services, Inc. , Specialty drug spend makes up ...
Breaking Medicine News(10 mins):Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2
... - 20% U.S. Sequential Quarterly Sales Increase - ... - FY08 Revenue Projection Raised - ... - Conference Call to be Held at 10:00 a.m. Central Time Today -, ... for the second quarter,of fiscal 2008 ended September 30, 2007, up 73% from $1.8 million ...
... Adults Reap Significant Benefits in Less than a ... American Council on Exercise,(ACE), your premier certification, education ... study that examined functional,fitness programming for older adults; ... world benefits relatively quickly. With the goal of ...
... parameters published in the November 1 issue of the ... and treatment of circadian rhythm sleep disorders (CRSDs). ... behavior, patient outcomes and possibly health care costs. , ... practice parameters, commissioned content experts in CRSDs to review ...
... BERKELEY, Calif., Nov. 1 Dynavax Technologies,Corporation (Nasdaq: ... the third,quarter and nine months ended September 30, ... of today,s arrangement with Merck. As of ... securities and investments held by Symphony Dynamo, Inc. ...
... LONDON, Nov. 1 Chiltern, a leading global clinical,research organization ... at,the Annual Partnerships in Clinical Trials Conference; which will be ... Exhibit and,Congress Center. Chiltern will sponsor "welcome coffee breaks" from ... 9:00 am on Nov. 7th. Chiltern will,also be present at ...
... time when the U.S. spends more than double what other ... Commonwealth Fund seven-nation survey finds that U.S. patients are more ... because of costs, and to say that the health care ... with Canadians, are also the least likely to be able ...
Cached Medicine News:Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 2Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 3Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 4Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 5Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 6Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 7Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 8Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 9Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 10Health News:Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter 11Health News:Exclusive American Council on Exercise (ACE) Research Study Proves Functional Fitness Really Works 2Health News:Practice parameters discuss the evaluation, treatment of circadian rhythm sleep disorders 2Health News:Practice parameters discuss the evaluation, treatment of circadian rhythm sleep disorders 3Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 2Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 3Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 4Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 5Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 6Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 7Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 8Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 9Health News:Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam 2Health News:US adults most likely to report medical errors and skip needed care due to costs 2Health News:US adults most likely to report medical errors and skip needed care due to costs 3Health News:US adults most likely to report medical errors and skip needed care due to costs 4
Inquire...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
Medicine Products: